Drug intelligence / Profile preview

HxB2.WT.Core-C4b

Development stage: Phase 1
Lead developer: International AIDS Vaccine Initiative
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

HxB2.WT.Core-C4b is an experimental HIV vaccine immunogen designed to boost and further mature broadly neutralizing antibody (bnAb)-precursor B-cell lineages elicited by a priming immunogen (426c.Mod.Core-C4b). It is derived from the HxB2 HIV Env protein and targets the CD4-binding site of HIV envelope. In current clinical trials, it is adjuvanted with 3M-052 AF + Alum and used as a booster following priming with 426c.Mod.Core-C4b.

Targets

gp120 (HIV-1 envelope glycoprotein (gp120/gp41) epitopes)

Beyond the preview

Go deeper on HxB2.WT.Core-C4b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HxB2.WT.Core-C4b.

Explore the full profile